Dyne Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Dyne Therapeutics, Inc. - overview
Established
2018
Location
Waltham, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2018 and led by CEO John Cox, operates as a provider of biotechnology platform that develops and provides muscle-targeted therapies to treat patients with muscle diseases such as myotonic dystrophy type 1. In May 2024, Dyne Therapeutics Inc. raised USD 325. 5 million in a private placement, selling 10.
5 million shares at USD 31 per share on the NASDAQ under the ticker symbol "DYN". Dyne Therapeutics Inc. has granted the underwriters a 30-day option to purchase up to an additional 1. 57 million shares of common stock.
Dyne Therapeutics Inc. provides muscle-targeted therapies in the biopharmaceutical field. The company’s pipeline includes promising clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), with a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). In addition, the firm offers preclinical data from the FORCE platform in delivering enzyme replacement therapy to muscle and the central nervous system in Pompe disease.
Current Investors
Atlas Venture, Forbion, MPM BioImpact
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.dyne-tx.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Dyne Therapeutics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Placement/Follow on | Completed | Dyne Therapeutics, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | Dyne Therapeutics, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | Dyne Therapeutics, Inc. | - |
Displaying 1 - 3 of 3
Dyne Therapeutics, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM | ||||||
| Member, Scientific Advisory Board | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.